Product approval information is indicated for:
•Control and prevention of bleeding in patients with hemophilia A or acquired Factor VIII (FVIII) deficiency (1.1)
•Surgical and/or invasive procedures in adult and pediatric patients with von Willebrand Disease in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery (1.2)
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/eZdO7jN
No comments:
Post a Comment